According to a recent study published in the journal JAMA Neurology, type 2 diabetes is associated with a diminished risk of amyotrophic lateral sclerosis (ALS). The study revealed that the risk is directly associated with the age at diagnosis of diabetes and the age at diagnosis of…
In a new study entitled “Dietary Vitamin D3 Restriction Exacerbates Disease Pathophysiology in the Spinal Cord of the G93A Mouse Model of Amyotrophic Lateral Sclerosis,” researchers evaluated the effects of a Vitamin D dietary restriction in the pathogenesis of Amyotrophic lateral sclerosis. The study was performed with…
Dr. Erik P. Pioro at the Neurological Institute, Cleveland Clinic in Ohio conducted a review on clinical data supporting treatment with dextromethorphan (DM) hydrobromide combined with quinidine sulfate (Q) for a disorder called pseudobulbar affect (PBA) that can occur in amyotrophic lateral sclerosis (ALS) patients. The study was published…
A neural prosthetic device surgically implanted in Erik G. Sorto, 34, left quadriplegic by gunshot wound 13 years ago, has enabled the single father of two to now move a robotic arm via only thought input. This major breakthrough is the outcome of a clinical collaboration between The California Institute…
A new study conducted by researchers at the Universidad Nacional Autónoma de México in Mexico recently revealed new insights into the mechanisms underlying motor neuron degeneration, offering potential new treatment strategies for amyotrophic lateral sclerosis (ALS). The study is entitled “Degeneration of spinal motor neurons by…
A new study led by researchers at the Mayo Clinic and recently published in the journal Science reported a new, important mouse model that allows the study of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, two relevant neurodegenerative diseases. The study is entitled “…
French pharmaceutical company AB Science SA has organized a web conference to present information on its lead product for the treatment of amyotrophic lateral sclerosis (ALS), a drug therapy called masitinib. The seminar held by AB Science, which is specialized in developing and commercializing protein…
The Annual Drug Company Working Group and the American Academy of Neurology (AAN) meetings were recently held by the ALS Association last month in Washington, D.C. with main focus on amyotrophic lateral sclerosis (ALS). The association is now sharing the most important data presented at the…
May is Awareness Month for amyotrophic lateral sclerosis (ALS). The ALS Association is celebrating this year in hopes of topping the huge awareness that was generated last summer through the ALS Ice Bucket Challenge and the incredibly enormous impact it had on the fight against the disease. To continue the momentum, The Association…
BrainStorm Cell Therapeutics Inc. has presented promising results on the Phase 2a clinical trial of its product NurOwn® for amyotrophic lateral sclerosis (ALS) at the 67th American Academy of Neurology Annual Meeting, which took place this year in Washington D.C from April 18-25. The presented poster was entitled…
Get regular updates to your inbox.
